Use of Monoclonal Antibodies Therapy for Treatment of Mild to Moderate COVID-19 in 4 Patients with Rheumatologic Disorders4명의 류마티스 질환 환자에서 경증에서 중등도의 COVID-19 치료를 위한 단일클론항체 요법의 사용Case Reports Published on 2021-11-252022-09-12 Journal: Medical science monitor : international medical jo [Category] MERS, SARS, 진단, [키워드] adverse outcomes case sery conducted Coronavirus disease 2019 Corticosteroid COVID-19 disease Diseases effective therapy Efficacy EUA FDA form hospital illness immunosuppressive increase information MAT a Mild moderate monoclonal antibody Patient protocol receiving retrospective rheumatological rheumatological disorder risk Safe therapy treated treating COVID-19 [DOI] 10.12659/MSM.934267 PMC 바로가기 [Article Type] Case Reports
Response to COVID-19 Vaccination Post-CAR T Therapy in Patients with Non-Hodgkin Lymphoma and Multiple MyelomaConference abstract Published on 2021-11-232022-10-05 Journal: Blood [Category] 유전자 메커니즘, [키워드] addition Affect antibody Antibody Response Antibody titer Antigen AstraZeneca authors average Bayer Bluebird BMS board Cancer CAR Cell cellular immunity Characteristics conducted COVID COVID-19 COVID-19 antibody COVID-19 infection COVID-19 vaccination COVID-19 vaccine CRBN current Daichii Sankyo Debiopharm Deceased died download education eligible evaluated False positive figure for inclusion Frequency funding Genmab Glaxo healthy donors hematologic Hematologic malignancy humoral IgG antibody Immunocompromised Immunoglobulin immunologic response immunosuppressive individual Infection janssen life majority malignancies Mayo Clinic median medical records Mortality multicenter Multiple Multiple myeloma Myeloma national guideline NHL Non-Hodgkin Lymphoma offered Patent Patient Pfizer populations positive receive receptor recipient recipients Regeneron reported response Retrospective study SARS-CoV-2 Seattle Seroconversion seroconversion rate small sample size speaker submission survived T-cell tested the timing the vaccine Therapeutics therapy Treatment Trillium vaccination [DOI] 10.1182/blood-2021-151859 [Article Type] Conference abstract
Gilteritinib for Relapsed Acute Myeloid Leukaemia with FLT3 Mutation during the COVID-19 Pandemic: Real World Experience from the UK National Health ServiceConference abstract Published on 2021-11-232022-10-05 Journal: Blood [Category] 변종, [키워드] 95%CI Administered Allogeneic AML approved ASXL1 board Cell Chemotherapy clinically clinician collected Complete COVID-19 COVID-19 pandemic criteria curative database de novo disease domain dose download duplication education effective ELN European experience figure FLT3 Follow-up funding Gilteritinib haematological disorder healthcare hospital Hospital admission IDH1 IDH2 immunosuppressive infected with SARS-CoV-2 information inhibitor Intensive Jazz less majority male median median age Morphological Mortality Most patient mutated Mutation mutations myeloid National Health Service network neutropenia NHS nosocomial not differ NPM1 outcome pandemic Patient patients performance status Physicians proceed reached reducing Registered reported resource resources response Result risk RUNX1 Sequencing significantly speaker Support survival Takeda the median therapy Toxicity TP53 Transmission Treatment tyrosine United Kingdom [DOI] 10.1182/blood-2021-150169 [Article Type] Conference abstract
Reduced antibody activity against SARS-CoV-2 B.1.617.2 delta virus in serum of mRNA-vaccinated individuals receiving tumor necrosis factor-α inhibitors종양 괴사 인자-α 억제제를 투여받는 mRNA 백신 접종 개인의 혈청에서 SARS-CoV-2 B.1.617.2 델타 바이러스에 대한 항체 활성 감소Clinical and Translational Article Published on 2021-11-182022-09-14 Journal: Med (New York, N.Y.) [Category] SARS, 변종, 진단, 치료법, [키워드] Abstract acute respiratory syndrome administration Alpha Analysis antibody Antibody Response B.1.351 B.1.617.2 BNT162b2 BNT162b2 mRNA vaccine center chronic inflammatory disease Cohort Context coronavirus coronavirus disease COVID-19 dose evaluated Fc effector functions finding function capacity funding immunization Immunocompromised immunocompromised individuals immunogenic Immunosuppression immunosuppressive immunosuppressive drug in healthy individuals individual individuals inhibitor inhibitors Innovation less longitudinal lowest monoclonal antibodies monotherapy mRNA vaccine Necrosis neutralization Neutralizing neutralizing antibody Neutralizing antibody titer Neutralizing titer neutralizing titers NIAID Pfizer populations Prevent Prophylaxis protective immunity receiving recipients reduced reductions in required response SARS-CoV-2 SARS-COV-2 infection serum serum antibody serum antibody response Serum neutralizing antibody severe disease strain supported susceptible tested Therapies therapy threshold TNF inhibitors TNF-α treated tumor necrosis factor-α vaccination Vaccine vaccine dose variant variants variants of concern virus [DOI] 10.1016/j.medj.2021.11.004 PMC 바로가기 [Article Type] Clinical and Translational Article
Dexamethasone modulates immature neutrophils and interferon programming in severe COVID-19Dexamethasone은 심각한 COVID-19에서 미성숙 호중구와 인터페론 프로그래밍을 조절합니다Article Published on 2021-11-152022-09-10 Journal: Nature Medicine [Category] MERS, SARS, 바이오마커, 유전자 메커니즘, 임상, 진단, 치료법, [키워드] activated acute respiratory distress acute respiratory distress syndrome affected affecting ARDS Bacterial cellular interaction cellular interactions characterized circulating neutrophils coronavirus disease Coronavirus disease 2019 COVID-19 Critical Defense develop Dexamethasone downregulated driver Effect expansion Host host defense IFN immature neutrophil immune immune cells immunosuppressive Immunotherapy information Innate innate immune cell Innate immune cells Innate immunity interferon interferon-stimulated gene interferon-stimulated genes mechanism modulate molecular mechanism molecular mechanisms neutrophil Neutrophils New outcomes Pathogens pathologic Patient plasma proteomics programming proportion prostaglandin respiratory respiratory distress Respiratory distress syndrome Respiratory pathogens severe COVID-19 Signaling single-cell Single-cell RNA sequencing steroid syndrome Target identification Therapeutic benefit viral infection [DOI] 10.1038/s41591-021-01576-3 PMC 바로가기 [Article Type] Article
Comparison of Interleukin-6 Plasma Concentration in Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 and Pediatric SepsisPediatrics Published on 2021-11-152022-10-31 Journal: Frontiers in Pediatrics [Category] COVID-19, [키워드] Admission analyzed both groups CDC criteria children children with MIS-C Clinical outcome clinical outcomes collected data Concentration COVID-19 Critically ill CRP datasets demographics described diagnosed Diagnosis difference driven by dysregulated immune response elevated excluded female IL-6 IL-6 inhibitor IL-6 level immunodeficiency immunosuppressive individual inflammatory biomarkers intensive care Interleukin-6 (IL-6) International Mechanical MIS-C Mortality much lower no difference no significant difference off-label Older Patient patient data PCT plasma plasma concentration Primary outcome procalcitonin Protein question retrospective cohort study SARS-CoV-2 SARS-COV-2 infection Sepsis septic Septic shock Sex Shock significantly higher Standard therapy statistically subgroup analysis therapy thought Vasoactive Ventilation was done [DOI] 10.3389/fped.2021.756083 PMC 바로가기 [Article Type] Pediatrics
Immunosuppressants in Liver Transplant Recipients With Coronavirus Disease 2019: Capability or Catastrophe?—A Systematic Review and Meta-AnalysisMedicine Published on 2021-11-112022-10-31 Journal: Frontiers in Medicine [Category] COVID-19, [키워드] age Analysis Cardiopulmonary carried Chronic kidney disease CKD Comorbidities Comorbidity Complete coronavirus coronavirus disease COVID-19 database diabetes diagnosis of COVID-19 disease disorders eight heterogeneity hypertension Immunosuppressant Immunosuppression immunosuppressive immunosuppressive therapy inhibitor key consideration less liver liver transplant lowest mammalian Meta-analysis MMF Mortality mortality rate obesity organ pooled rate Prognosis Rapamycin recipient regimen rejection replaced review risk SARS-CoV-2 searched selected severe disease severity significantly Steroids survival the disease the patient therapy Transplant with COVID-19 Withdrawal [DOI] 10.3389/fmed.2021.756922 PMC 바로가기 [Article Type] Medicine
Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis다발성 경화증에서 COVID-19 중증도와 질병 수정 요법의 연관성41 Published on 2021-11-092022-09-12 Journal: Neurology [Category] MERS, SARS, 진단, [키워드] 95% CI 95% confidence interval Acetate adjusted adjusted odds ratio Admission admitted to ICU age Alemtuzumab analyzed artificial ventilation association Characteristics Cladribine Cohort coronavirus disease Coronavirus disease 2019 country covariate covariates COVID-19 COVID-19 cases COVID-19 severity cross-sectional design death demographic demonstrated died dimethyl fumarate disability EDSS EDSS score examined fumarate Glatiramer Glatiramer acetate higher risk Hospitalization Hospitalized ICU ICU admission immunosuppressive include increased risk indication intensive care intensive care unit interferon internal and external International Logistic regression Multiple multiple sclerosis Natalizumab objective Ocrelizumab Older age outcome outcomes Patient phenotype reflected required restriction Result risk factor rituximab scale sclerosis severe coronavirus disease severe COVID-19 severity Sex Siponimod status Stratification therapy Ventilation were assessed with COVID-19 [DOI] 10.1212/WNL.0000000000012753 PMC 바로가기 [Article Type] 41
Recurrence of COVID-19 in a Patient With NMO Spectrum Disorder While Treating With Rituximab: A Case Report and Review of the Literature리툭시맙 치료 중 NMO 스펙트럼 장애 환자의 COVID-19 재발: 사례 보고 및 문헌 검토Review Published on 2021-11-042022-09-12 Journal: The neurologist [Category] MERS, 진단, [키워드] acute respiratory syndrome Asymptomatic COVID-19 coronavirus disease Coronavirus-2 COVID-19 COVID-19 pandemic develop diagnosed discharged home Disease activity disorder Evidence exhibited immunosuppressive Intravenous immunoglobulin invasive literature management Moderate COVID-19 neurological Oxygenation pandemic Patient raise readmission recurrence report respiratory symptom review Spectrum therapy treating virus while [DOI] 10.1097/NRL.0000000000000371 PMC 바로가기 [Article Type] Review
Belatacept Use after Kidney Transplantation and Its Effects on Risk of Infection and COVID-19 Vaccine ResponseReview Published on 2021-11-032022-10-30 Journal: Journal of Clinical Medicine [Category] COVID-19, [키워드] addition Area belatacept CD80/CD86 CMV CNI COVID-19 COVID-19 infection cytomegalovirus database de novo disease Effect eight expert greater Immunosuppression immunosuppressive immunosuppressive regimen Impact increased risk kidney Kidney transplantation mechanism Older opportunistic Infections Patient Pneumonia receiving recipient respond poorly response risk risk of infection safety profile SARS-CoV-2 vaccination therapy toxicities transplantation Vaccines [DOI] 10.3390/jcm10215159 PMC 바로가기 [Article Type] Review